UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 637

Sortiert nach

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.799-807

2012

Link zum Volltext

Verfügbarkeit prüfen

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Journal of hematology and oncology, 2017-02, Vol.10 (1), p.55-14, Article 55

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

Blood, 2009-03, Vol.113 (10), p.2161-2171

2009

Link zum Volltext

Verfügbarkeit prüfen

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Blood, 2016-06, Vol.127 (26), p.3360-3368

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

The Lancet (British edition), 2008-02, Vol.371 (9610), p.395-403

2008

Link zum Volltext

Verfügbarkeit prüfen

Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

British journal of haematology, 2013-05, Vol.161 (3), p.411-423

2013

Link zum Volltext

Verfügbarkeit prüfen

Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin

JAMA internal medicine, 2014-06, Vol.174 (6), p.947

2014

Link zum Volltext

Verfügbarkeit prüfen

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy

British journal of haematology, 2017-09, Vol.178 (6), p.906-913

2017

Link zum Volltext

Verfügbarkeit prüfen

Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials

The Lancet. Haematology, 2014-10, Vol.1 (1), p.e37-e46

2014

Link zum Volltext

Verfügbarkeit prüfen

AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP

The New England journal of medicine, 2006-10, Vol.355 (16), p.1672-1681

2006

Link zum Volltext

Verfügbarkeit prüfen

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

Journal of clinical oncology, 2009-04, Vol.27 (11), p.1850-1856

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

Journal of clinical oncology, 2010-02, Vol.28 (4), p.549-555

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

Journal of clinical oncology, 2010-01, Vol.28 (3), p.437-444

2010

Link zum Volltext

Verfügbarkeit prüfen

Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry

Leukemia research, 2014-02, Vol.38 (2), p.149-154

2014

Link zum Volltext

Verfügbarkeit prüfen

Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study

Clinical lymphoma, myeloma and leukemia, 2022-07, Vol.22 (7), p.e532-e540

2022

Link zum Volltext

Verfügbarkeit prüfen

MPN-186 Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden: Analysis of Data from the MOST Study

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22 Suppl 2, p.S329

2022

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Journal of hematology and oncology, 2012-11, Vol.5 (1), p.71-71, Article 71

2012

Link zum Volltext

Verfügbarkeit prüfen

Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim

International journal of hematology, 2015-09, Vol.102 (3), p.259-270

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia

Haematologica (Roma), 2017-08, Vol.102 (8), p.1342

2017

Link zum Volltext

Verfügbarkeit prüfen

Myelodysplastic Syndromes: Therapy and Outlook

The American journal of medicine, 2012-07, Vol.125 (7), p.S18-S23

Lyons, Roger M., MD, FACP

2012

Link zum Volltext

Verfügbarkeit prüfen

Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years

Leukemia research, 2017-05, Vol.56, p.88-95

2017

Link zum Volltext

Verfügbarkeit prüfen

MPN-077 Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 3022 Patients With Polycythemia Vera (PV) Treated in US Community Practices

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22 Suppl 2, p.S325

2022

Link zum Volltext

Verfügbarkeit prüfen

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Blood cancer journal (New York), 2023-09, Vol.13 (1), p.147-147, Article 147

2023

Link zum Volltext

Verfügbarkeit prüfen

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

The oncologist (Dayton, Ohio), 2018-02, Vol.23 (2), p.159-170

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 637

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(410)
Mit Volltextzugriff
(597)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy

Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials

AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study

MPN-186 Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden: Analysis of Data from the MOST Study

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia

Myelodysplastic Syndromes: Therapy and Outlook

Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years

MPN-077 Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 3022 Patients With Polycythemia Vera (PV) Treated in US Community Practices

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

Suchergebnisse filtern